entertainment -WSS

entertainment

author：knowledge 2025-09-30 12:10:22 - browse：2758

A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Pediatric cancer treatments threatened by a new FDA policy

WSS

U.K. Biobank has 500,000 peoples' genome sequences available

Astellas still sees hope in its gene therapy after four deaths

What to do when lifesaving products contribute to climate change

Readout Newsletter: Bayer study halts, Carmot to IPO, and more

Gain of function research would be limited under House proposal

PBM reforms clear House panel

entertainment

entertainment

knowledge

Virginia high school admissions case could be legal follow

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Hollywood unions extend contract negotiations for actors

Congress must reauthorize a committee to support older Americans

Apple is now the first public company to be valued at $3 trillion

Fetal surgery at risk from Dobbs and new abortion restrictions

Affirmative action in medical school literally saved lives

With clinical trial data readouts, here's how to spot spin

Novavax promises a turnaround & Lilly roils the obesity market

As biotech industry slumps, bioscience job market is upside down

Wikipedia

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

U.K. considers world's first use of meningitis vaccine to address gonorrhea

U.K. Biobank has 500,000 peoples' genome sequences available

With clinical trial data readouts, here's how to spot spin

ReNAgade cuts staff seven months after raising $300 million

FDA's Woodcock to retire early next year

leisure time

Wikipedia

knowledge

entertainment